Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer : a substudy of the neoadjuvant GeparQuinto trial
| Autor: | Sibylle Loibl, Ralf Kronenwett, Iris Schrader, Silvia Darb-Esfahani, Petra Krabisch, Michael Untch, Georg Kunz, Manfred Dietel, Jörg-Olaf Habeck, Thorsten Kühn, Yasmin Issa-Nummer, Gunter von Minckwitz, Bruno Valentin Sinn, Marianne Just, Valentina Nekljudova, Hans-Ullrich Ulmer, Friedrich Overkamp, Kurt Diebold, Jens-Uwe Blohmer, Carsten Denkert, Frank Holms |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Oncology
Adult Bridged-Ring Compounds medicine.medical_specialty Anthracycline Receptor ErbB-2 medicine.medical_treatment lcsh:Medicine Breast Neoplasms Lymphocytic Infiltrate 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Anthracyclines Lymphocytes Prospective Studies ddc:610 Prospective cohort study lcsh:Science Neoadjuvant therapy 030304 developmental biology Aged 0303 health sciences Multidisciplinary Predictive marker Taxane business.industry lcsh:R Middle Aged medicine.disease Neoadjuvant Therapy 3. Good health 030220 oncology & carcinogenesis lcsh:Q Female Taxoids business Breast carcinoma Research Article |
| Zdroj: | PLoS ONE PLoS ONE, Vol 8, Iss 12, p e79775 (2013) |
| Popis: | Introduction We have recently described an increased lymphocytic infiltration rate in breast carcinoma tissue is a significant response predictor for anthracycline/taxane-based neoadjuvant chemotherapy (NACT). The aim of this study was to prospectively validate the tumor-associated lymphocyte infiltrate as predictive marker for response to anthracycline/taxane-based NACT. Patients and Methods The immunological infiltrate was prospectively evaluated in a total of 313 core biopsies from HER2 negative patients of the multicenter PREDICT study, a substudy of the neoadjuvant GeparQuinto study. Intratumoral lymphocytes (iTuLy), stromal lymphocytes (strLy) as well as lymphocyte-predominant breast cancer (LPBC) were evaluated by histopathological assessment. Pathological complete response (pCR) rates were analyzed and compared between the defined subgroups using the exact test of Fisher. Results Patients with lymphocyte-predominant breast cancer (LPBC) had a significantly increased pCR rate of 36.6%, compared to non-LPBC patients (14.3%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|